New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program

Noboru Takada; Takaharu Okada; Eri Kogawa; Yohsuke Sanada; Ayumi Ishidoya

doi:doi:10.11648/j.jddmc.20190503.11

| Peer-Reviewed

New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program

Noboru Takada, Takaharu Okada, Eri Kogawa, Yohsuke Sanada, Ayumi Ishidoya

Published in Journal of Drug Design and Medicinal Chemistry (Volume 5, Issue 3)

Received: 16 July 2019 Accepted: 7 August 2019 Published: 23 August 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Hypertension is currently one of the most serious health issues worldwide. Nicotianamine, a non-peptide-type amino acid trimer, is ubiquitously present in higher plants and plays a role as an internal metal transporter. It is known that nicotianamine inhibits ACE activity and that oral treatment with the compound improves hypertension. However the mode of action remains unclear, due to lack of crystallographic data. Although a structure-activity relationship study of nicotianamine has the potential to uncover the details of the inhibition profile, the azetidine-2-carboxylic acid moiety in nicotianamine has become a critical barrier for further biochemical research due to limited commercial supply and difficulties with structural modification. In this paper, ten nicotianamine analogs without azetidine-2-carboxylic acid moiety were prepared and their inhibition of angiotensin I-converting enzyme was investigated. Among these analogs, a phenylalanine analog, (2S,3′S,3″S)-N-{3′-(3″-amino-3″-carboxypropylamino)-3′-carboxypropyl}phenylalanine, displayed the most potent activity. The inhibition activity of the compound corresponded to that of captopril. These results suggested a possibility of structural modification of nicotianamie to develop antihypertensive drugs. Molecular docking studies with Gold were also performed to predict the binding poses of nicotianamine and its analog, suggesting that nicotianamine and its analogs combine a plausible allosteric site in an area away from the catalytic site in ACE.

Published in	Journal of Drug Design and Medicinal Chemistry (Volume 5, Issue 3)
DOI	10.11648/j.jddmc.20190503.11
Page(s)	33-39
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Nicotianamine, Structure-Activity-Relationship Study, Angiotensin I-Converting Enzyme Inhibitors, Molecular Docking Study, Allosteric Binding Site

References

[1]	M. A. Ondetti, B. Rubin D. W. Cushman Design of specific inhibitors of angiotensin converting enzyme; new class of orally active antihypertensive agents. Science, Vol 196, 1977, pp 441-444.
[2]	A. B. AtkinsonJ. I. S. Robertson Captopril in the treatment of clinical hypertension and cardiac failure. Lancet, Vol 314, 1979, pp 836-839.
[3]	E. M. Salar, S. I. Bastacky, E. K. JacksonS. P. Tofovic Captopril attenuates cardiovascular and renal disease in a rat model of heart failure with preserved ejection fraction. J. Cardiovasc. Pharmacol., Vol 71, 2018, pp 205-214.
[4]	R. Natesh, S. L. U. Schwager, H. R. Evans, E. D. SturrockK. R. Acharya Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry, Vol 43, 2004, pp 8718-8724.
[5]	A. A. Patchett, E. Harris, E. W. Tristram, M. J. Wyvratt, M. T. Wu, D. Taub, E. R. Peterson, T. J. Ikeler, J. ten Broeke, L. G. Payne, D. L. Ondeyka, E. D. Thorsett, W. J. Greenlee, N. S. Lohr, R. D. Hoffsommer, H. Joshua, W. V. Ruyle, J. W. Rothrock, S. D. Aster, A. L. Maycock, F. M. Robinson, R. Hirschmann, C. S. Sweet, E. H. Ulm, D. M. Gross, T. C. VassilC. A. Stone A new class of angiotensin-converting enzyme inhibitors. Nature, Vol 288, 1980, pp 280-283.
[6]	M. Noma, M. NoguchiE. Tamaki A new amino acid, nicotianamine, from tabacco leaves. Tetrahedron Lett., Vol 12, 1971, pp 2017-2020.
[7]	M. Takahashi, Y. Terada, I. Nakai, H. Nakanishi, E. Yoshimura, S. MoriN. K. Nishizawa Role of nicotianamine in the intracellular delivery of metals and plant reproductive development. Plant Cell, Vol 15, 2003, pp 1263-1280.
[8]	R. K. Kumar, H. -H. Chu, C. Abundis, K. Vasques, D. C. Rodriguez, J. -C. Chia, R. Huang, O. K. VatamaniukE. L. Walker Iron-nicotianamine transporters are required for proper long distance iron signaling. Plant Physiol., Vol 175, 2017, pp 1254-1268.
[9]	T. Nozoye, M. Otani, T. Senoura, H. NakanishiN. K. Nishizawa Overexpression of barley nicotianamine synthase 1 confers tolerance in the sweet potato to iron deficiency in calcareous soil. Plant Soil, Vol 418, 2017, pp 75-88.
[10]	E. Kinoshita, J. YamakoshiM. Kikuchi Purification and identification of an angiotensin I-converting enzyme inhibitor from soy sauce. Biosci. Biotechnol. Biochem., Vol 57, 1993, pp 1107-1110.
[11]	A. Hayashi, T. Nakayama, K. Murakami, Y. AoyagiK. Kimoto Effects of nicotianamine on blood pressure in Tsukuba hypertensive mice (THM). J. Jpn. Soc. Nutr. Food Sci., Vol 58, 2005, pp 315-321.
[12]	S. Takahashi, T. Yoshiya, K. Yoshizawa-KumagayeT. Sugiyama Nicotianamine is a new angiotensin-converting enzyme 2 inhibitor in soybean. Biomed. Res., Vol 36, 2015, pp 219-224.
[13]	K. Higuchi, S. Watanabe, M. Takahashi, S. Kawasaki, H. Nakanishi, N. K. NishizawaS. Mori Nicotianamine synthase gene expression differs in barley and rice under Fe-deficient conditions. Plant J., Vol 25, 2001, pp 159-167.
[14]	D. Mizuno, K. Higuchi, T. Sakamoto, H. Nakanishi, S. MoriN. K. Nishizawa Three nicotianamine synthase genes isolated from maize are differentially regulated by iron nutritional status. Plant Physiol., Vol 132, 2003, pp 1989-1997.
[15]	S. Kim, M. Takahashi, K. Higuchi, K. Tsunoda, H. Nakanishi, E. Yoshimura, S. MoriN. K. Nishizawa Increased nicotianamine biosynthesis confers enhanced tolerance of high levels of metals, in particular nickel, to plants. Plant Cell Physiol., Vol 46, 2005, pp 1809-1818.
[16]	A. HayashiK. Kimoto Nicotianamine preferentially inhibits angiotensin I-converting enzyme. J Nutr Sci Vitaminol, Vol 53, 2007, pp 331-336.
[17]	M. Hayakari, K. Satoh, H. Izumi, T. Kudoh, J. Asano, T. YamazakiS. Tsuchida Kinetic-controlled hydrolysis of Leu-Val-Val-hemorphin-7 catalyzed by angiotensin-converting enzyme from rat brain. Peptides, Vol 24, 2003, pp 1075-1082
[18]	M. Hayakari, R. Seito, A. Furugori, Y. HashimotoS. Murakami An improved colorimetric assay of angiotensin-converting enzyme in serum. Clin. Chem. Acta, Vol 144, 1984, pp 71-75.
[19]	S. Fushiya, S. Nakatsuyama, Y. SatoS. Nozoe Synthesis of nicotianamine and a related compound, rerivatives of azetidine-2-carboxylic acid. Heterocycles, Vol 15, 1981, pp 819-822.
[20]	Y. Ohfune, M. TomitaK. Nomoto Total synthesis of 2’-deoxymugineic acid, the metal chelator excreted from wheat root. J. Am. Chem. Soc., Vol 103, 1981, pp 2409-2410.
[21]	F. Matsuura, Y. HamadaT. Shioiri Total synthesis of 2'-deoxymugineic acid and nicotianamine. Tetrahedron, Vol 50, 1994, pp 9457-9470.
[22]	K. Miyakoshi, J. OshitaT. Kitahara Expeditious synthesis of nicotianamine and 2'-deoxymugineic acid. Tetrahedron, Vol 57, 2001, pp 3355-3360.
[23]	M. Bouazaoui, S. Mari, P. Czernic, C. Curie, J. MartinezF. Cavelier Synthesis and biological activity of nicotianamine and analogues. Adv. Exp. Med. Biol., Vol 611, 2009, pp 555-557.
[24]	G. Jones, P. WillettR. C. Glen Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol., Vol 245, 1995, pp 43-53.
[25]	G. Jones, P. Willett, R. C. Glen, A. R. LeachR. Taylor Development and validation of fa genetic algorithm for flexible docking. J. Mol. Biol., Vol 267, 1997, pp 727-748.
[26]	N. S. Pagadala, K. SyedJ. Tuszynski Software for molecular docking; a review. Biophys. Rev., Vol 9, 2017, pp 91-102.
[27]	N. A. Roberts, J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. KayA. Kröhn Rational design of peptide-based HIV proteinase inhibitors. Science, Vol 248, 1990, pp 358-361.
[28]	O. M. Becker, D. S. Dhanoa, Y. Marantz, D. Chen, S. Shacham, S. Cheruku, A. Heifetz, P. Mohanty, M. Fichman, A. Sharadendu, R. Nudelman, M. KauffmanS. Noiman An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J. Med. Chem., Vol 49, 2006, pp 3116-3135.
[29]	K. K. Reddy, S. K. Singh, S. K. TripathiC. Selvaraj Identification of potential HIV-1 integrase strand transfer inhibitors; in silico virtual screening and QM/MM docking studies. . SAR QSAR Environ. Res., Vol 24, 2013, pp 581-595.
[30]	C. A. Hunter MELDORA LECTURE. The role fo aromatic interactions in molecular recognition. Chem. Soc. Rev., Vol 23, 1994, pp 101-109.
[31]	T. Böttcher, M. Pitscheider S. A. Sieber Natural products and their biological targets; proteomic and metabolomic labeling strategies. Angew. Chem. Int. Ed., Vol 49, 2010, pp 2680-2698.
[32]	S. Sato, A. Murata, T. Shirakawa M. Uesugi Biochemical target isolation for novices; affinity-based strategies. Chem. Biol., Vol 17, 2010, pp 616-623.
[33]	F. Kotzyba-Hibert, I. KapferM. Goeldner Recent trends in photoaffinitylabeling. Angew. Chem. Int. Ed. Engl., Vol 34, 1995, pp 1296-1312.
[34]	M. Hashimoto Y. Hatanaka Recent progress in dazirine-based photoaffinity labeling. Eur. J. Org. Chem., Vol 2008, 2008, pp 2513-2523.

Cite This Article

Plain Text BibTeX RIS

APA Style

Noboru Takada, Takaharu Okada, Eri Kogawa, Yohsuke Sanada, Ayumi Ishidoya. (2019). New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. Journal of Drug Design and Medicinal Chemistry, 5(3), 33-39. https://doi.org/10.11648/j.jddmc.20190503.11

Copy | Download

ACS Style

Noboru Takada; Takaharu Okada; Eri Kogawa; Yohsuke Sanada; Ayumi Ishidoya. New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. J. Drug Des. Med. Chem. 2019, 5(3), 33-39. doi: 10.11648/j.jddmc.20190503.11

Copy | Download

AMA Style

Noboru Takada, Takaharu Okada, Eri Kogawa, Yohsuke Sanada, Ayumi Ishidoya. New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. J Drug Des Med Chem. 2019;5(3):33-39. doi: 10.11648/j.jddmc.20190503.11

Copy | Download

@article{10.11648/j.jddmc.20190503.11,
  author = {Noboru Takada and Takaharu Okada and Eri Kogawa and Yohsuke Sanada and Ayumi Ishidoya},
  title = {New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program},
  journal = {Journal of Drug Design and Medicinal Chemistry},
  volume = {5},
  number = {3},
  pages = {33-39},
  doi = {10.11648/j.jddmc.20190503.11},
  url = {https://doi.org/10.11648/j.jddmc.20190503.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jddmc.20190503.11},
  abstract = {Hypertension is currently one of the most serious health issues worldwide. Nicotianamine, a non-peptide-type amino acid trimer, is ubiquitously present in higher plants and plays a role as an internal metal transporter. It is known that nicotianamine inhibits ACE activity and that oral treatment with the compound improves hypertension. However the mode of action remains unclear, due to lack of crystallographic data. Although a structure-activity relationship study of nicotianamine has the potential to uncover the details of the inhibition profile, the azetidine-2-carboxylic acid moiety in nicotianamine has become a critical barrier for further biochemical research due to limited commercial supply and difficulties with structural modification. In this paper, ten nicotianamine analogs without azetidine-2-carboxylic acid moiety were prepared and their inhibition of angiotensin I-converting enzyme was investigated. Among these analogs, a phenylalanine analog, (2S,3′S,3″S)-N-{3′-(3″-amino-3″-carboxypropylamino)-3′-carboxypropyl}phenylalanine, displayed the most potent activity. The inhibition activity of the compound corresponded to that of captopril. These results suggested a possibility of structural modification of nicotianamie to develop antihypertensive drugs. Molecular docking studies with Gold were also performed to predict the binding poses of nicotianamine and its analog, suggesting that nicotianamine and its analogs combine a plausible allosteric site in an area away from the catalytic site in ACE.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program
AU  - Noboru Takada
AU  - Takaharu Okada
AU  - Eri Kogawa
AU  - Yohsuke Sanada
AU  - Ayumi Ishidoya
Y1  - 2019/08/23
PY  - 2019
N1  - https://doi.org/10.11648/j.jddmc.20190503.11
DO  - 10.11648/j.jddmc.20190503.11
T2  - Journal of Drug Design and Medicinal Chemistry
JF  - Journal of Drug Design and Medicinal Chemistry
JO  - Journal of Drug Design and Medicinal Chemistry
SP  - 33
EP  - 39
PB  - Science Publishing Group
SN  - 2472-3576
UR  - https://doi.org/10.11648/j.jddmc.20190503.11
AB  - Hypertension is currently one of the most serious health issues worldwide. Nicotianamine, a non-peptide-type amino acid trimer, is ubiquitously present in higher plants and plays a role as an internal metal transporter. It is known that nicotianamine inhibits ACE activity and that oral treatment with the compound improves hypertension. However the mode of action remains unclear, due to lack of crystallographic data. Although a structure-activity relationship study of nicotianamine has the potential to uncover the details of the inhibition profile, the azetidine-2-carboxylic acid moiety in nicotianamine has become a critical barrier for further biochemical research due to limited commercial supply and difficulties with structural modification. In this paper, ten nicotianamine analogs without azetidine-2-carboxylic acid moiety were prepared and their inhibition of angiotensin I-converting enzyme was investigated. Among these analogs, a phenylalanine analog, (2S,3′S,3″S)-N-{3′-(3″-amino-3″-carboxypropylamino)-3′-carboxypropyl}phenylalanine, displayed the most potent activity. The inhibition activity of the compound corresponded to that of captopril. These results suggested a possibility of structural modification of nicotianamie to develop antihypertensive drugs. Molecular docking studies with Gold were also performed to predict the binding poses of nicotianamine and its analog, suggesting that nicotianamine and its analogs combine a plausible allosteric site in an area away from the catalytic site in ACE.
VL  - 5
IS  - 3
ER  -

Copy | Download

Author Information

Noboru Takada

Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan
Takaharu Okada

Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan
Eri Kogawa

Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan
Yohsuke Sanada

Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan
Ayumi Ishidoya

Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Noboru Takada, Takaharu Okada, Eri Kogawa, Yohsuke Sanada, Ayumi Ishidoya. (2019). New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. Journal of Drug Design and Medicinal Chemistry, 5(3), 33-39. https://doi.org/10.11648/j.jddmc.20190503.11

Copy | Download

ACS Style

Noboru Takada; Takaharu Okada; Eri Kogawa; Yohsuke Sanada; Ayumi Ishidoya. New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. J. Drug Des. Med. Chem. 2019, 5(3), 33-39. doi: 10.11648/j.jddmc.20190503.11

Copy | Download

AMA Style

Noboru Takada, Takaharu Okada, Eri Kogawa, Yohsuke Sanada, Ayumi Ishidoya. New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program. J Drug Des Med Chem. 2019;5(3):33-39. doi: 10.11648/j.jddmc.20190503.11

Copy | Download

@article{10.11648/j.jddmc.20190503.11,
  author = {Noboru Takada and Takaharu Okada and Eri Kogawa and Yohsuke Sanada and Ayumi Ishidoya},
  title = {New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program},
  journal = {Journal of Drug Design and Medicinal Chemistry},
  volume = {5},
  number = {3},
  pages = {33-39},
  doi = {10.11648/j.jddmc.20190503.11},
  url = {https://doi.org/10.11648/j.jddmc.20190503.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jddmc.20190503.11},
  abstract = {Hypertension is currently one of the most serious health issues worldwide. Nicotianamine, a non-peptide-type amino acid trimer, is ubiquitously present in higher plants and plays a role as an internal metal transporter. It is known that nicotianamine inhibits ACE activity and that oral treatment with the compound improves hypertension. However the mode of action remains unclear, due to lack of crystallographic data. Although a structure-activity relationship study of nicotianamine has the potential to uncover the details of the inhibition profile, the azetidine-2-carboxylic acid moiety in nicotianamine has become a critical barrier for further biochemical research due to limited commercial supply and difficulties with structural modification. In this paper, ten nicotianamine analogs without azetidine-2-carboxylic acid moiety were prepared and their inhibition of angiotensin I-converting enzyme was investigated. Among these analogs, a phenylalanine analog, (2S,3′S,3″S)-N-{3′-(3″-amino-3″-carboxypropylamino)-3′-carboxypropyl}phenylalanine, displayed the most potent activity. The inhibition activity of the compound corresponded to that of captopril. These results suggested a possibility of structural modification of nicotianamie to develop antihypertensive drugs. Molecular docking studies with Gold were also performed to predict the binding poses of nicotianamine and its analog, suggesting that nicotianamine and its analogs combine a plausible allosteric site in an area away from the catalytic site in ACE.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - New ACE Inhibitor Designed from Nicotianamine and Its Docking Pose Prediction Using the Gold Program
AU  - Noboru Takada
AU  - Takaharu Okada
AU  - Eri Kogawa
AU  - Yohsuke Sanada
AU  - Ayumi Ishidoya
Y1  - 2019/08/23
PY  - 2019
N1  - https://doi.org/10.11648/j.jddmc.20190503.11
DO  - 10.11648/j.jddmc.20190503.11
T2  - Journal of Drug Design and Medicinal Chemistry
JF  - Journal of Drug Design and Medicinal Chemistry
JO  - Journal of Drug Design and Medicinal Chemistry
SP  - 33
EP  - 39
PB  - Science Publishing Group
SN  - 2472-3576
UR  - https://doi.org/10.11648/j.jddmc.20190503.11
AB  - Hypertension is currently one of the most serious health issues worldwide. Nicotianamine, a non-peptide-type amino acid trimer, is ubiquitously present in higher plants and plays a role as an internal metal transporter. It is known that nicotianamine inhibits ACE activity and that oral treatment with the compound improves hypertension. However the mode of action remains unclear, due to lack of crystallographic data. Although a structure-activity relationship study of nicotianamine has the potential to uncover the details of the inhibition profile, the azetidine-2-carboxylic acid moiety in nicotianamine has become a critical barrier for further biochemical research due to limited commercial supply and difficulties with structural modification. In this paper, ten nicotianamine analogs without azetidine-2-carboxylic acid moiety were prepared and their inhibition of angiotensin I-converting enzyme was investigated. Among these analogs, a phenylalanine analog, (2S,3′S,3″S)-N-{3′-(3″-amino-3″-carboxypropylamino)-3′-carboxypropyl}phenylalanine, displayed the most potent activity. The inhibition activity of the compound corresponded to that of captopril. These results suggested a possibility of structural modification of nicotianamie to develop antihypertensive drugs. Molecular docking studies with Gold were also performed to predict the binding poses of nicotianamine and its analog, suggesting that nicotianamine and its analogs combine a plausible allosteric site in an area away from the catalytic site in ACE.
VL  - 5
IS  - 3
ER  -

Copy | Download